GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Flexion Therapeutics Inc (NAS:FLXN) » Definitions » Return-on-Tangible-Asset

Flexion Therapeutics (Flexion Therapeutics) Return-on-Tangible-Asset : -56.66% (As of Sep. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Flexion Therapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Flexion Therapeutics's annualized Net Income for the quarter that ended in Sep. 2021 was $-121.2 Mil. Flexion Therapeutics's average total tangible assets for the quarter that ended in Sep. 2021 was $214.0 Mil. Therefore, Flexion Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2021 was -56.66%.

The historical rank and industry rank for Flexion Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

FLXN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -104.64   Med: -47.24   Max: -31.74
Current: -42.91

During the past 10 years, Flexion Therapeutics's highest Return-on-Tangible-Asset was -31.74%. The lowest was -104.64%. And the median was -47.24%.

FLXN's Return-on-Tangible-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.91 vs FLXN: -42.91

Flexion Therapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Flexion Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Flexion Therapeutics Return-on-Tangible-Asset Chart

Flexion Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.69 -41.19 -46.04 -58.36 -48.44

Flexion Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.83 -30.50 -47.37 -40.34 -56.66

Competitive Comparison of Flexion Therapeutics's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Flexion Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Flexion Therapeutics's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Flexion Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Flexion Therapeutics's Return-on-Tangible-Asset falls into.



Flexion Therapeutics Return-on-Tangible-Asset Calculation

Flexion Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2020 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=-113.706/( (217.56+251.926)/ 2 )
=-113.706/234.743
=-48.44 %

Flexion Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2021 )  (Q: Jun. 2021 )(Q: Sep. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2021 )  (Q: Jun. 2021 )(Q: Sep. 2021 )
=-121.248/( (210.047+217.931)/ 2 )
=-121.248/213.989
=-56.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2021) net income data.


Flexion Therapeutics  (NAS:FLXN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Flexion Therapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Flexion Therapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Flexion Therapeutics (Flexion Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10 Mall Road, Suite 301, Burlington, MA, USA, 01803
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra-articular corticosteroid treatment.
Executives
Mark S. Levine officer: General Counsel 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Kerry Wentworth officer: Chief Regulatory Officer AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Christina Willwerth officer: Chief Strategy Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Melissa Layman officer: Chief Commercial Officer C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803
Scott Kelley officer: Chief Medical Officer C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505
Elizabeth Kwo director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael D. Clayman director, officer: President and CEO C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Alan Milinazzo director C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078
Scott A Canute director FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
C Ann Merrifield director
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Samuel D Colella director, 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Patrick J Mahaffy director C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301
Mark Stejbach director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Flexion Therapeutics (Flexion Therapeutics) Headlines

From GuruFocus